Jun 2026 (Q2 FY26) — Aug 4, 2026
Pacira BioSciences Q2 FY26 — Strategic Execution and Pipeline Advancement
Read the full callPacira BioSciences (PCRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pacira BioSciences earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 192 | +6.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 2.2 | −2.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$36.34 0.00% · $0
Performance +58.9% 1Y
1Y: $22.87 on 17 Oct 2025 → $36.34. High $36.4 (14 Oct 2026), low $19.16 (16 Jan 2026).
- Previous close
- $36.34
- 52-week range
- $19.16 – $36.4
- One year
- +57.86%
Overview
- Symbol
- PCRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pacira BioSciences earnings calls (PCRX)
Financials
What the filings say
Net profit, year on year: +196% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 169 | 187 | 169 | 181 | 180 | 197 | 177 | 192 |
| Expenses | 308 | 163 | 167 | 173 | 173 | 195 | 170 | 188 |
| Operating profit | -140 | 25 | 2 | 8 | 6 | 2 | 7 | 4 |
| Operating margin | −82.8% | 13.2% | 1.2% | 4.7% | 3.5% | 1.2% | 3.9% | 2.2% |
| Other income | 1 | 1 | 7 | -10 | 3 | -2 | -2 | -2 |
| Interest | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Profit before tax | -139 | 26 | 9 | -2 | 10 | 1 | 5 | 3 |
| Tax rate | −3.3% | 37.2% | 44.7% | −151.5% | 43.0% | −186.7% | 41.7% | −82.1% |
| Net profit | -143 | 16 | 5 | -5 | 5 | 2 | 3 | 5 |
| EPS ($ per share) | -3.11 | — | 0.10 | -0.11 | 0.12 | — | 0.07 | 0.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -388 | -399 | -254 | -212 | -149 | -107 | -206 | -199 |
| Total liabilities | 368 | 476 | 655 | 1,345 | 906 | 704 | 775 | 572 |
| Fixed assets | 109 | 105 | 137 | 188 | 184 | 174 | 167 | 141 |
| Investments | 251 | 214 | 422 | 71 | 185 | 125 | 208 | 80 |
| Total assets | 689 | 831 | 1,275 | 2,075 | 1,681 | 1,574 | 1,554 | 1,265 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 49 | 71 | 77 | 126 | 145 | 155 | 189 | 152 |
| Cash from investing | 21 | -128 | -278 | -21 | -225 | 78 | -83 | 99 |
| Cash from financing | 9 | 4 | 222 | 381 | -402 | -183 | 17 | -370 |
| Net cash flow | 78 | -54 | 22 | 486 | -481 | 49 | 123 | -118 |
| Capital expenditure | -15 | -10 | -38 | -46 | -30 | -15 | -11 | -15 |
| Free cash flow | 34 | 60 | 39 | 80 | 115 | 139 | 179 | 137 |
Insider filings
50 filings between Oct 31, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.75M
17 sales by 5 insiders
94% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Cross Shawn | — | $1.52M | Apr 23, 2026 |
| WILLIAMS KRISTEN | — | $498.2K | Jun 4, 2026 |
| RIKER LAUREN | — | $479.2K | Oct 8, 2026 |
| SLONIN JONATHAN | — | $240.4K | Aug 17, 2026 |
| Froimson Mark | — | $10.9K | Mar 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | RIKER LAUREN Senior Vice President, Finance | Option exercise 10b5-1 plan | 6,000 | $194.1K |
| Oct 8, 2026 | RIKER LAUREN Senior Vice President, Finance | Sale 10b5-1 plan | 6,000 | $217.9K |
| Aug 17, 2026 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 plan | 3,040 | $70.6K |
| Jun 11, 2026 | RIKER LAUREN Senior Vice President, Finance | Sale 10b5-1 plan | 6,115 | $143.7K |
| Jun 10, 2026 | Young Alethia Director | Award | 6,405 | $0 |
| Jun 10, 2026 | CHRISTIE CHRISTOPHER Director | Award | 6,405 | $0 |
| Jun 10, 2026 | Hirawat Samit Director | Award | 6,405 | $0 |
| Jun 10, 2026 | Brege Laura Director | Award | 6,405 | $0 |
| Jun 10, 2026 | Froimson Mark Director | Award | 6,405 | $0 |
| Jun 10, 2026 | BIGAL MARCELO Director | Award | 6,405 | $0 |
| Jun 10, 2026 | YANG MICHAEL J. Director | Award | 6,405 | $0 |
| Jun 4, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Sale 10b5-1 plan | 10,259 | $228.5K |
| Jun 3, 2026 | SLONIN JONATHAN Chief Medical Officer | Tax withheld | 4,728 | $105.5K |
| Jun 3, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Tax withheld 10b5-1 plan | 8,528 | $190.3K |
| Jun 3, 2026 | RIKER LAUREN Senior Vice President, Finance | Tax withheld | 3,187 | $71.1K |
| Apr 23, 2026 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 12,941 | $212.9K |
| Apr 23, 2026 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 12,941 | $325.6K |
| Apr 22, 2026 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 1,500 | $24.7K |
| Apr 22, 2026 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 1,500 | $37.5K |
| Apr 21, 2026 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 2,845 | $46.8K |
| Apr 21, 2026 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 2,845 | $71.2K |
| Apr 20, 2026 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 7,714 | $126.9K |
| Apr 20, 2026 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 7,714 | $193.9K |
| Mar 17, 2026 | Froimson Mark Director | Sale | 500 | $10.9K |
| Mar 17, 2026 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 plan | 3,261 | $74.4K |
| Feb 11, 2026 | SLONIN JONATHAN Chief Medical Officer | Award | 54,546 | $0 |
| Feb 11, 2026 | Lee Frank D. Chief Executive Officer | Award | 261,818 | $0 |
| Feb 11, 2026 | RIKER LAUREN Senior Vice President, Finance | Award | 19,273 | $0 |
| Feb 11, 2026 | Teehan Brendan Chief Commercial Officer | Award | 51,714 | $0 |
| Feb 11, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Award | 54,546 | $0 |
| Feb 11, 2026 | Cross Shawn Chief Financial Officer | Award | 49,091 | $0 |
| Feb 2, 2026 | RIKER LAUREN Senior Vice President, Finance | Sale 10b5-1 plan | 4,000 | $83.2K |
| Feb 2, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Sale 10b5-1 plan | 13,137 | $269.7K |
| Jan 30, 2026 | SLONIN JONATHAN Chief Medical Officer | Tax withheld | 6,168 | $126.7K |
| Jan 30, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Tax withheld 10b5-1 plan | 17,134 | $351.9K |
| Jan 30, 2026 | RIKER LAUREN Senior Vice President, Finance | Tax withheld 10b5-1 plan | 2,751 | $56.5K |
| Jan 30, 2026 | Lee Frank D. Chief Executive Officer | Tax withheld | 41,488 | $852.2K |
| Jan 30, 2026 | Teehan Brendan Chief Commercial Officer | Tax withheld | 5,182 | $106.4K |
| Jan 5, 2026 | RIKER LAUREN Senior Vice President, Finance | Sale 10b5-1 plan | 1,416 | $34.3K |
| Jan 2, 2026 | RIKER LAUREN Senior Vice President, Finance | Tax withheld 10b5-1 plan | 159 | $3.9K |
| Jan 2, 2026 | Lee Frank D. Chief Executive Officer | Tax withheld | 9,272 | $226.8K |
| Jan 2, 2026 | SLONIN JONATHAN Chief Medical Officer | Tax withheld | 381 | $9.3K |
| Dec 31, 2025 | Teehan Brendan Chief Commercial Officer | Award | 402 | $4.3K |
| Dec 10, 2025 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 9,104 | $228.9K |
| Dec 10, 2025 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 9,104 | $149.8K |
| Dec 9, 2025 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 plan | 15,896 | $261.5K |
| Dec 9, 2025 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 15,896 | $397.9K |
| Nov 17, 2025 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 plan | 3,960 | $95.4K |
| Nov 10, 2025 | Cross Shawn Chief Financial Officer | Sale 10b5-1 plan | 12,060 | $266.4K |
| Oct 31, 2025 | Cross Shawn Chief Financial Officer | Tax withheld | 6,690 | $143.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Pacira BioSciences, Inc.
Free account. Everything above stays public.
Write why you follow Pacira BioSciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading